Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Neutral

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

YS Biopharma Co., Ltd. Ordinary Shares (YS)

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/17/2023

Market Cap

192,094,560

Shares Outstanding

93,060,000

Weighted SO

93,058,197

Total Employees

N/A

Upcoming Earnings

08/20/2024

Similar Tickers

REVB --.--%

CDIO --.--%

BDRX --.--%

ZVSA --.--%

SONN --.--%

ALLR --.--%

KRBP --.--%

IMMX --.--%

CNSP --.--%

Beta

0.5360

Last Div

0.0000

Range

0.3503-1.78

Chg

0.0900

Avg Vol

130559

Mkt Cap

192094560

Exch

NASDAQ

Country

CN

Phone

86 10 8920 2086

DCF Diff

N/A

DCF

0.0000

Div Yield

0.0000

P/S

2.2207

EV Multiple

-6.0931

P/FV

1.4331

Div Yield %

0.0000

P/E

-2.2268

PEG

0.0625

Payout

0.0000

Current Ratio

0.9363

Quick Ratio

0.7088

Cash Ratio

0.2522

DSO

237.4297

DIO

557.4248

Op Cycle

794.8545

DPO

226.6024

CCC

568.2521

Gross Margin

0.7985

Op Margin

-0.5051

Pretax Margin

-0.5627

Net Margin

-0.4928

Eff Tax Rate

-0.0223

ROA

-0.2022

ROE

-0.5046

ROCE

-0.4988

NI/EBT

0.8758

EBT/EBIT

1.1139

EBIT/Rev

-0.5051

Debt Ratio

0.3661

D/E

1.1654

LT Debt/Cap

0.2139

Total Debt/Cap

0.5382

Int Coverage

-20.9724

CF/Debt

0.0000

Equity Multi

3.1831

Rec Turnover

1.5373

Pay Turnover

1.6108

Inv Turnover

0.6548

FA Turnover

1.0895

Asset Turnover

0.4103

OCF/Share

0.0000

FCF/Share

0.0000

Cash/Share

2.3922

OCF/Sales

0.0000

FCF/OCF

0.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

1.4331

P/B

1.4331

P/S

2.2207

P/E

-2.2268

P/FCF

0.0000

P/OCF

0.0000

P/CF

0.0000

PEG

0.0625

P/S

2.2207

EV Multiple

-6.0931

P/FV

1.4331

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 16, 05:42 Share repurchase programme: Transactions of week 24 2025 GlobeNewswire Inc. Jun 16, 05:42 Aktietilbagekøb: Transaktioner i uge 24 2025 GlobeNewswire Inc. May 28, 04:30 Lerøy Seafood Group ASA: Eks. utbytte i dag GlobeNewswire Inc. May 15, 04:30 Lerøy Seafood Group ASA: Strong biological performance and continued growth in VAP S&D. GlobeNewswire Inc. May 07, 05:41 Delårsrapport 1. kvartal 2025 GlobeNewswire Inc. May 07, 05:41 Interim Financial Report, Q1 2025 GlobeNewswire Inc. May 07, 01:04 ENR FutureTech 2025 Day 1 Wrap-Up: AI, Digital Twins, and a Bold Vision for Construction’s Future GlobeNewswire Inc. Apr 07, 04:30 Lerøy Seafood Group ASA: Trading update Q1 2025 The Motley Fool Apr 02, 23:07 Why Lumentum Holdings Stock Leaped More Than 5% Skyward on Wednesday GlobeNewswire Inc. Mar 29, 18:30 Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) The Motley Fool Mar 13, 03:30 Tilly's (TLYS) Q4 2024 Earnings Call Transcript GlobeNewswire Inc. Mar 05, 00:30 Global Calcite Market to Reach USD 21,407.4 Million by 2035 at a CAGR of 5.9%, Driven by Increasing Demand in Construction, Paints & Coatings, Plastics, and Pharmaceuticals Sector | FMI GlobeNewswire Inc. Feb 28, 05:30 Lerøy Seafood Group ASA: Strong quarter reflects operational improvements. Good progress towards 2025 targets. The Motley Fool Dec 06, 02:45 Tilly's (TLYS) Q3 2024 Earnings Call Transcript GlobeNewswire Inc. Nov 14, 05:30 Lerøy Seafood Group ASA: Fortsatt fremgang i biologisk prestasjon, i et kvartal med lave laksepriser GlobeNewswire Inc. Oct 04, 05:43 Conclusion of share repurchase programme GlobeNewswire Inc. Oct 04, 05:43 Afslutning af aktietilbagekøbsprogram GlobeNewswire Inc. Sep 13, 00:10 Free Zones and Human Capital: The Dominican Republic’s Formula for Leading nearshoring in the Region The Motley Fool Sep 06, 01:15 Tilly's (TLYS) Q2 2024 Earnings Call Transcript GlobeNewswire Inc. Aug 21, 04:30 Lerøy Seafood Group ASA: Continued progress in biological performance

Revenue Product Segmentation